CN105879055A - CXCR4 small-molecular RNA loaded polyamide dendrimer nano microparticles - Google Patents
CXCR4 small-molecular RNA loaded polyamide dendrimer nano microparticles Download PDFInfo
- Publication number
- CN105879055A CN105879055A CN201410631214.9A CN201410631214A CN105879055A CN 105879055 A CN105879055 A CN 105879055A CN 201410631214 A CN201410631214 A CN 201410631214A CN 105879055 A CN105879055 A CN 105879055A
- Authority
- CN
- China
- Prior art keywords
- cxcr4
- microrna
- polyamide
- solution
- small
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to CXCR4 small-molecular RNA loaded polyamide dendrimer nano microparticles and a preparation method thereof, and is characterized in that with PAMAM dendrimers as a carrier, a CXCR4 small-molecular RNA and the PAMAM dendrimers form a polyamide dendrimer CXCR4 small-molecular RNA cross-linking compound according to the mass ratio of 1:0.73, and the particle size of the microparticles comprises the average particle size of 176.5 nm at the temperature of 25 DEG C. The obtained nano microparticles have the advantages of small particle size, high encapsulation rate for the small-molecular RNA, large carrying capacity, increase of cell transfection efficiency, and efficient and specific small-molecular interference technology. During treatment of disease, the nano microparticles are used in kidney cancer resistant treatment, and increase the treatment effect of genetic resistance to kidney cancer.
Description
Technical field
The present invention relates to a kind of newtype drug dosage form, be specially and carry CXCR4 microRNA polyamide dendroid
Polymer nano particle and preparation method thereof.
Background technology
CXCL12 (stromal cell-derived factorl, SDF-1) be chemotactic because of
One newcomer of Zijia race, its unique receptor Chemokine receptor4 (chemokine receptor4, CXCR4)
Wide expression is on many tissues and organ.The most relevant research in recent years shows that SDF-1/CXCR4 is raw
Thing axle plays an important role at aspects such as the transfer of kidney cancer cell, apoptosis.The overexpression of CXCR4,
The propagation of kidney cancer cell can be promoted, suppress the expression of CXCR4 then can play induction Change of Apoptosis in Renal Cancer Cells
Effect, and the transfer of renal carcinoma is played the effect of suppression.
Antisense technology is a kind of effective gene treatment means of oncotherapy research in recent years, for closing deleterious gene
Express, block tumor development and there is important value.In various antisense means, the ribose recently occurred
Nucleic acid interference (RNA interference, RNAi) technology is the most noticeable, refers to by double-strand
RNA (double-stranded RNA, dsRNA) molecule closes the mistake of corresponding sequence gene expression in mRNA level in-site
Journey, has feature special, efficient, as emerging Gene silence, will grind in human gene function
Study carefully, gene therapy aspect has huge application prospect.And shRNA is to close most in the RNA interference technology
The effector molecule of key.
Nanotechnology as a new branch of science Cross slot interference to other numerous ambits, in biological medicine
The outstanding behaviours in field is that it has broad application prospects as pharmaceutical carrier.The most external employing is gathered
The poly lactic-co-glycolic acid that amide-amine type dendritic (PAMAM dendrimers) used relatively in the past
The nano-carriers such as copolymer (PLGA) compare have that carrying amount is bigger, permeable membrane ability is higher, slow-releasing more preferably,
Many advantages such as harmless, but it is showed no polyamide-amine type branch-shape polymer the most both at home and abroad
Carry the report of CXCR4 microRNA.
Summary of the invention
It is an object of the invention to 7 generation (G7) polyamide-amine type branch-shape polymer as carrier,
It is combined with CXCR4 microRNA, prepares load CXCR4 microRNA polyamide dendroid and gather
Compound nanoparticle.This nanoparticle can be bigger improve the carrying amount of microRNA, transfection efficiency, strengthen
The targeting specific of microRNA, and to human non-toxic, preferably improve CXCR4 microRNA and resist
Renal carcinoma therapeutic effect.
The above-mentioned load CXCR4 microRNA polyamide dendroid polymer nano particle that the present invention proposes specifically is made
Standby step is as follows:
The accurate 1 OD microRNA that extracts is centrifuged, and dilutes with the ultra-pure water of 45 microlitres, obtains solution A；Take
15 microlitre 7 PAMAM type dendritic (G7For PAMAM dendrimers) solution is micro-with 30
Rise ultra-pure water and dilute to obtain solution B；Take B solution 1 microlitre to be diluted to 15 microlitres and obtain solution C；Take solution A 1
Microlitre, C solution 5 microlitre, add in 15 uL serum-free media, make CXCR4 microRNA with poly-
The mass ratio of amide-amine type dendritic is 1: 0.73, at room temperature hatches 10 minutes, obtains load
CXCR4 microRNA polyamide dendroid polymer nano particle.
The Nano medication of the present invention is with polyamide-amine type branch-shape polymer as carrier, molecule little with CXCR4
RNA is cross-linked with each other formation nanoparticle.This kind of nanoparticle mean diameter is 176.5 nanometers at 25 DEG C, and
Can preferably protect microRNA damage in vitro.
The carrier of above-mentioned microgranule is 7 PAMAM type dendritics.
The belongings of above-mentioned microgranule are CXCR4 microRNA.
Above-mentioned nanoparticle has carries RNA amount greatly, and the advantages such as protectiveness is good can improve turning of microRNA
Dye rate.
In the present invention, nano-carrier used can be that each generation polyamide dendrimer one therein (includes G1、
G2、G3、G4、G5、G6Deng).
In the present invention, medium used is serum-free medium.
The load CXCR4 microRNA polyamide dendroid polymer nano particle that the present invention develops, its average particle
Footpath is 176.5 nanometers at 25 DEG C.
The load CXCR4 microRNA polyamide dendroid polymer nano particle that the present invention develops, it carries RNA
Amount can be carried out by the mass ratio of regulation CXCR4 microRNA and polyamide-amine type branch-shape polymer
Adjust, can reach fully wrapped around with the ratio of 1: 0.73.
At present, the research carrying microRNA in the world biases toward with liposome, virus as carrier more, this
The Nano microsphere of bright development has the advantage that 1, novel nano carrier polyamide-amine type branch-shape polymer
Belong to non-biological material, nontoxic to human body cell, there is no immunogenicity yet, organism immune response will not be caused；
2 is different from viral vector, hereditary-less toxicity and cytotoxicity；3, due to its special dendritic structure (tool
Have great specific surface), carry microRNA amount big；4, after nano-carrier combines with microRNA,
MicroRNA segment can be preferably protected not degraded by RNase；5, novel nano carrier can significantly improve little
Molecule RNA transfection rate, improves intracellular concentration；6, microRNA technology has feature special, efficient,
Can substantially suppress the expression of survivin gene；7, this carrier system can discharge medicine slowly, remains effective
Drug level；8 compare with the medicine-carried system of the mediation such as plasmid, virus, have preferable external controllable property.
Detailed description of the invention
The beneficial effect of medicine of the present invention it is further elucidated with below by way of test.
Test example 1. carries CXCR4 microRNA polyamide dendroid polymer nano particle to kidney cancer cell (A498)
Inhibitory action
Use mtt assay to observe and carry CXCR4 microRNA polyamide dendroid polymer nano particle to renal carcinoma
The inhibitory action of cell proliferation.This experiment is divided into the three groups: 1st group of CXCR4 microRNA solution, and (it is dense
Degree is respectively 0.1,1.0,10 μm ol/L), the 2nd group carries the polymerization of CXCR4 microRNA polyamide dendroid
Thing nanoparticle solution (its CXCR4 microRNA actual concentrations is corresponding identical with the 1st group), the 3rd group is gathered
Amide dendrimer solution (its quality is corresponding identical with the 2nd group), often group sets 3 multiple holes, with not dosing
Thing group is blank.24h after dosing respectively, after 48h, 72h add MTT solution continuation cultivation 4h,
After removing supernatant, add DMSO 150 μ l/ hole, shake, dissolve, at 570nm wavelength, measure absorbance
Value (A570), and calculate suppression ratio, suppression ratio=(the 1-experimental group average A570/ average A570 of matched group)
× 100%.The results are shown in Table 1.
CXCR4 microRNA and the load CXCR4 microRNA polyamide dendroid of table 1 variable concentrations gather
The impact that renal carcinoma A498 cell is grown by compound nanoparticle
By MTT experiment it can be shown that load CXCR4 microRNA polyamide dendroid polymer nanometer is micro-
Grain can substantially suppress the propagation of A498 cell, and along with the prolongation of drug treating time, the increasing of drug level
Adding, its inhibition is the most obvious.Additionally, at identical drug level and under same action time, carry CXCR4
The microRNA polyamide dendroid polymer nano particle inhibitory action CXCR4 to be exceeded to A498 cell
MicroRNA group.
The detection of test example 2.RT-PCR carries CXCR4 microRNA polyamide dendroid polymer nano particle
The expression of A498 cell CXCR4 mRNA after transfection
Use RT-PCR method to observe and carry the transfection of CXCR4 microRNA polyamide dendroid polymer nano particle
Inhibitory action to CXCR4 mrna expression after A498 cell.By A498 cell by 5 × 106/ ware is inoculated into training
Support in ware, in each culture dish, be separately added into three groups of medicines (little molecule of CXCR4 of first group: 10umo/L
RNA solution, second group: containing the load CXCR4 microRNA polyamide of identical CXCR4 microRNA concentration
Dendroid polymer nano particle solution, the 3rd group: with the polyamide dendroid polymer of second group of homogenous quantities
Complete culture solution), after 48h cultivates, collect cell, extract cell total rna and reverse transcription cDNA behaviour
Making, data acquisition instrument carries software (ABI Prism 7300) and is analyzed, the target gene of each sample
Relative mRNA expression levels calculate as follows: relatively mrna expression=2-ΔCt× 100%, Δ Ct value=
Target gene Ct value-GAPDH Ct value.The results are shown in Table 2.
The RT-PCR testing result of 2 three groups of cell CXCR4 mrna expressions of table
RT-PCR testing result show carry CXCR4 microRNA polyamide dendroid polymer nano particle group with
The mrna expression of CXCR4 microRNA group is respectively 1.24% and 3.06%, the table of the former CXCR4 mRNA
Reach 40.5% for the latter.
It is an object of the invention to 7 generation (G7) polyamide-amine type branch-shape polymer as carrier, will
It combines with CXCR4 microRNA, prepares load CXCR4 microRNA polyamide dendroid polymerization
Thing nanoparticle.This nanoparticle can be bigger improve the carrying amount of microRNA, transfection efficiency, strengthen little
The targeting specific of molecule RNA, and to human non-toxic, preferably improve the anti-kidney of CXCR4 microRNA
Cancer therapeutic effect.In disease treatment, can be used for the treatment of anti-renal carcinoma, improve gene anti-renal carcinoma therapeutic effect.
Claims (3)
1. carrying a CXCR4 microRNA polyamide dendroid polymer nano particle, its composition includes polyamide
One amine type dendritic, CXCR4 microRNA, it is characterised in that gather with polyamide one amine type dendroid
Compound is carrier, and making CXCR4 microRNA is 1 with the mass ratio of polyamide one amine type dendritic:
0.73, form polyamide dendroid polymer survivin small molecule RNA cross-linked composite, microspherulite diameter is at 25 DEG C
Time mean diameter be 176.5 nanometers.
A kind of load CXCR4 microRNA polyamide dendroid polymer nanometer the most according to claim 1 is micro-
Grain, it is characterised in that prepared by following steps:
Take 1OD CXCR4 microRNA to be centrifuged, dilute with the ultra-pure water of 45 microlitres, obtain solution A；
Take 15 microlitre the 7th generation polyamide one amine type dendrimer solution to dilute with 30 microlitre ultra-pure waters
Solution B；
Take B solution 1 microlitre to be diluted to 15 microlitres and obtain solution C；
Take solution A 1 microlitre, C solution 5 microlitre, add in 15 uL serum-free media, make CXCR4
MicroRNA is 1: 0.73 with the mass ratio of polyamide one amine type dendritic, in incubated at room 10
Min, must carry CXCR4 microRNA polyamide dendroid polymer nano particle.
A kind of load CXCR4 microRNA polyamide dendroid polymer nanometer the most according to claim 1 is micro-
Grain is treated for anti-renal carcinoma in disease treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410631214.9A CN105879055A (en) | 2014-11-11 | 2014-11-11 | CXCR4 small-molecular RNA loaded polyamide dendrimer nano microparticles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410631214.9A CN105879055A (en) | 2014-11-11 | 2014-11-11 | CXCR4 small-molecular RNA loaded polyamide dendrimer nano microparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105879055A true CN105879055A (en) | 2016-08-24 |
Family
ID=56697942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410631214.9A Pending CN105879055A (en) | 2014-11-11 | 2014-11-11 | CXCR4 small-molecular RNA loaded polyamide dendrimer nano microparticles |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105879055A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022016120A1 (en) * | 2020-07-17 | 2022-01-20 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to injured kidney |
| US11931418B2 (en) | 2020-04-24 | 2024-03-19 | Ashvattha Therapeutics, Inc. | Methods of treating severe inflammation |
-
2014
- 2014-11-11 CN CN201410631214.9A patent/CN105879055A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11931418B2 (en) | 2020-04-24 | 2024-03-19 | Ashvattha Therapeutics, Inc. | Methods of treating severe inflammation |
| WO2022016120A1 (en) * | 2020-07-17 | 2022-01-20 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to injured kidney |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Functionalizing framework nucleic‐acid‐based nanostructures for biomedical application | |
| Dzmitruk et al. | Dendrimers show promise for siRNA and microRNA therapeutics | |
| Xin et al. | Nano-based delivery of RNAi in cancer therapy | |
| Zhang et al. | Anti-inflammatory and antioxidative effects of tetrahedral DNA nanostructures via the modulation of macrophage responses | |
| Sun et al. | Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo | |
| Sun et al. | Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy | |
| Shen et al. | Natural polyphenol inspired polycatechols for efficient siRNA delivery | |
| Biswas et al. | Dendrimers for siRNA delivery | |
| Costa et al. | MicroRNAs as molecular targets for cancer therapy: on the modulation of microRNA expression | |
| Liu et al. | Structurally flexible triethanolamine-core poly (amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics | |
| Fattal et al. | Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA | |
| Yin et al. | Overcoming chemoresistance in cancer via combined microRNA therapeutics with anticancer drugs using multifunctional magnetic core–shell nanoparticles | |
| Jere et al. | Poly (β-amino ester) as a carrier for si/shRNA delivery in lung cancer cells | |
| Kapadia et al. | Polymer nanocarriers for MicroRNA delivery | |
| Xu et al. | Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis | |
| Ly et al. | Pegylated dendrimer and its effect in fluorouracil loading and release for enhancing antitumor activity | |
| CN107001627A (en) | Composition for nucleic acid to be introduced to cell | |
| KR101494773B1 (en) | Drug Carrier Having L-DNA Nanocage Structure | |
| Liu et al. | Enzyme‐synthesized poly (amine‐co‐esters) as nonviral vectors for gene delivery | |
| Zhang et al. | PEGylated poly (amine-co-ester) micelles as biodegradable non-viral gene vectors with enhanced stability, reduced toxicity and higher in vivo transfection efficacy | |
| CN104258416B (en) | Deliver the nano-carrier and preparation method of drug and gene altogether based on oligonucleotide | |
| CN101768276B (en) | Methoxy polyethylene glycol-polycaprolactone-polyethyleneimine triblock copolymer and application thereof | |
| Manoharan et al. | Effect of molecular weight of polyethyleneimine on loading of CpG oligodeoxynucleotides onto flake-shell silica nanoparticles for enhanced TLR9-mediated induction of interferon-α | |
| CN106893054A (en) | A kind of cationic polymer gene vector and its preparation method and application | |
| Wu et al. | A strategy using mesoporous polymer nanospheres as nanocarriers of Bcl-2 siRNA towards breast cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160824 |